Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development
Open Access
- 19 January 2010
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (1), 34-48
- https://doi.org/10.1111/j.1476-5381.2009.00427.x
Abstract
Following reports of death from cardiac arrhythmias with drugs like terfenadine and cisapride, the International Conference for Harmonization formulated a guidance (E14) document. This specifies that all new drugs must undergo a 'thorough QT/QTc' (TQT) study to detect drug-induced QT prolongation, a surrogate marker of ventricular tachycardia, especially torsades de pointes (TdPs). With better understanding of data from several completed TQT studies, regulatory requirements have undergone some changes since the E14 guidance was implemented in October 2005. This article reviews the implications of the E14 guidance and the changes in its interpretation including choice of baseline QT, demonstration of assay sensitivity, statistical analysis of the effect of new drug and positive control, and PK-PD modelling. Some issues like use of automated QT measurements remain unresolved. Pharmaceutical companies too are modifying Phase 1 studies to detect QTc liability early in order to save time and resources. After the E14 guidance, development of several drugs that prolong QTc by >5 ms is being abandoned by sponsors. However, all drugs that prolong the QT interval do not increase risk of TdP. Researchers in regulatory agencies, academia and industry are working to find better biomarkers of drug-induced TdP which could prevent many useful drugs from being prematurely abandoned. Drug-induced TdP is a rare occurrence. With fewer drugs that prolong QT interval reaching the licensing stage, knowing which of these drugs are torsadogenic is proving to be elusive. Thus, paradoxically, the effectiveness of the E14 guidance itself has made prospective validation of new biomarkers difficult.This publication has 105 references indexed in Scilit:
- Keep the QT interval: It is a reliable predictor of ventricular arrhythmiasHeart Rhythm, 2008
- Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea‐pig modelBritish Journal of Pharmacology, 2008
- Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspectiveBritish Journal of Pharmacology, 2008
- Cellular basis of drug‐induced torsades de pointesBritish Journal of Pharmacology, 2008
- Guide to Receptors and Channels (GRAC), 3rd editionBritish Journal of Pharmacology, 2008
- Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointesEP Europace, 2007
- Sample sizes for clinical trials with Normal dataStatistics in Medicine, 2004
- Drug-Induced Prolongation of the QT IntervalThe New England Journal of Medicine, 2004
- Female gender as a risk factor for torsades de pointes associated with cardiovascular drugsJAMA, 1993
- Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmiaThe American Journal of Cardiology, 1991